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Human cytomegalovirus (HCMV) is an important human pathogen and a paradigm of intrinsic, innate 
and adaptive viral immune evasion. Here, we employed multiplexed tandem mass tag-based proteomics 
to characterise host proteins targeted for degradation late during HCMV infection. This approach 
revealed that mixed lineage kinase domain-like protein (MLKL), a key terminal mediator of cellular 
necroptosis, was rapidly and persistently degraded by the minimally passaged HCMV strain Merlin but 
not the extensively passaged strain AD169. The strain Merlin viral inhibitor of apoptosis pUL36 was 
necessary and sufficient both to degrade MLKL and to inhibit necroptosis. Furthermore, mutation of 
pUL36 Cys131 abrogated MLKL degradation and restored necroptosis. As the same residue is also 
required for pUL36-mediated inhibition of apoptosis by preventing proteolytic activation of procaspase-
8, we define pUL36 as a multifunctional inhibitor of both apoptotic and necroptotic cell death. 
SIGNIFICANCE STATEMENT 
Cell death is a key defence against viral infection, preventing spread from infected to uninfected cells. 
Correspondingly, certain viruses encode inhibitors of apoptotic and necroptotic cell death pathways in 
order to facilitate their persistence. Human cytomegalovirus (HCMV) is an important human pathogen 
that can block apoptosis, but hitherto it has been unclear whether or how the virus blocks necroptosis. 
Here, we used a proteomic screen to identify human proteins targeted for destruction by HCMV, finding 
that the key necroptosis mediator MLKL is degraded throughout infection. MLKL is targeted for 
degradation by HCMV protein pUL36, which is also instrumental in inhibiting apoptosis. Thus, pUL36 






Human cytomegalovirus (HCMV) infects the majority of the world’s population, with a seroprevalence 
of 60-80% in Western Europe and the USA, and up to 100% in developing countries (1, 2). Following 
primary infection, a latent infection is established that persists lifelong. Reactivation from latency to 
productive infection in immunocompromised people can lead to significant morbidity or mortality, in 
addition to allograft rejection in transplant recipients (3, 4). Furthermore, HCMV is the commonest 
infectious cause of congenital disease, affecting ~1/200 pregnancies (5). 
Only four drugs are approved by the FDA to treat HCMV, and all are associated with significant toxicity 
and the threat of drug resistance (2, 6). Small molecule-based disruption of interactions between 
antiviral host proteins and their viral antagonists could facilitate endogenous inhibition of viral 
replication (7, 8). Identification and detailed characterisation of such interactions thus has important 
implications for the development of novel anti-HCMV therapies. 
HCMV encodes 170 canonical protein-coding genes (2). A substantial number of additional, non-
canonical open reading frames (ORFs) that potentially encode proteins have been identified by 
ribosomal footprinting and proteomics (9, 10). During productive infection in vitro, expression of 
HCMV genes is conventionally divided into immediate-early, early and late phases during a ~96 h lytic 
replication cycle. Recently, five temporal classes of viral protein expression (Tp1-Tp5) have been 
defined by measuring viral protein profiles over the whole course of infection (11).  
Hijacking of the ubiquitin-proteasome system (UPS) to degrade host proteins is ubiquitous across many 
viral families (12). The proteins degraded by viruses are typically detrimental to viral replication, and 
can include antiviral restriction factors or components of viral sensing pathways, activating immune 
cell ligands, and elements of cell death pathways (13, 14). We have shown previously that >900 host 
proteins are downregulated >3-fold over the course of HCMV infection, with 133 proteins degraded 
during the early phase, of which 89% are targeted to the proteasome. These data led directly to the 
identification of candidate natural killer (NK) cell ligands and identified helicase-like transcription 
factor (HLTF) as a novel antiviral restriction factor (10, 11). However, it is not yet known which 
proteins are degraded later during infection, or throughout a whole infection time-course. Furthermore, 
it is unclear whether or how HCMV inhibits necroptotic cell death pathways, which represent a key 
defence against viral spread within an infected host (15).  
Activation of death receptors such as TRAILR1/2, TNFR1 and Fas leads to apoptotic cell death via an 
activating cleavage of procaspase-8 (16). In the presence of caspase inhibition or limiting levels of ATP, 
extrinsic apoptosis shifts towards the necroptotic pathway. This is dependent on an interaction between 
Receptor Interacting Serine/Threonine Kinases 1 and 3 (RIP1/3) through their homotypic interaction 
motif (RHIM) domains (17). Necroptosis can also be activated by cytoplasmic sensing of murine 
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cytomegalovirus (MCMV) DNA by Z-DNA-binding protein 1 (ZBP1), or ligation of Toll-like receptors 
3 or 4 (TLR3/4), which activate RIP3 through alternative RHIM domain-containing adaptors (17) 
(Figure 1). All three pathways converge with RIP3-dependent phosphorylation and activation of the 
pseudokinase MLKL, which transitions from an inactive monomer to a necroptotic oligomer. The 
oligomer translocates to and disrupts the plasma membrane, leading to cell swelling and loss of plasma 
membrane integrity, although the exact mechanism of membrane disruption is unclear (18–20). 
Here, a systematic examination of protein degradation at 48 h of HCMV infection determined that 
degradation of MLKL was sustained throughout early and late infection. The data showed that MLKL 
was degraded by the minimally-passaged Merlin strain of HCMV, but not by the highly passaged 
laboratory-adapted strain AD169. The strain Merlin UL36-encoded viral inhibitor of caspase-8 
activation (vICA/pUL36), which is known to function as a potent inhibitor of apoptosis, interacted with 
MLKL and was necessary and sufficient both to degrade MLKL and to inhibit TNFα-stimulated 
necroptosis. Whereas HCMV strain AD169 sensitised cells to necroptosis, strain Merlin prevented this 
sensitisation. pUL36 is thus a multifunctional cell death inhibitor capable of inhibiting both apoptotic 
and necroptotic pathways. 
RESULTS 
Host proteins targeted for degradation at 48 h of HCMV infection 
We applied the proteasomal inhibitor MG132 to build a global picture of proteins degraded late during 
HCMV infection. TERT-immortalised primary human fetal foreskin fibroblasts (HFFF-TERTs) were 
infected with HCMV strain Merlin at a multiplicity of infection (MOI) of 10 for 48 h, with application 
of MG132 (or the equivalent amount of DMSO as a control) for the final 12 h of infection (Figure 2A). 
MG132 is known to inhibit calpains and lysosomal cathepsins in addition to the proteasome (10), and 
was used to generate a comprehensive list of proteins targeted for degradation by HCMV rather than to 
identify proteins specifically degraded by the proteasome. 8,476 human and 186 viral proteins were 
quantified across two biological replicates (Dataset S1, which includes an interactive ‘Plotter’). Two 
ratios and associated significance values were calculated for each protein: (i) virus:mock infection and 
(ii) virus+MG132:virus infection (Figure 2B). 52 proteins met high confidence criteria for degradation, 
with a fold downregulation and rescue of >2 and p<0.05 for both ratios. 
From a comparison with our previous study of HCMV-induced protein degradation between 2-24 h 
(10), seven proteins were degraded with high confidence throughout early and late infection (Figures 
2C, 2D). These proteins included HLTF and Anaphase Promoting Complex subunits 1 and 5 
(ANAPC1/5), whose degradation by HCMV has been well characterised (10, 21). The effector of 
necroptosis MLKL was the most significantly downregulated protein at 48 h of HCMV infection and 
was among proteins most significantly rescued by addition of MG132 (Figure 2B). In comparison, 37 
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proteins degraded at 48 h did not score highly for degradation at early time points (10) (Figures 2C, 
2E, and SI Appendix, Figure S1A).  
Degradation of MLKL is mediated by immediate early protein pUL36 
We previously took a systematic approach to identifying the viral proteins responsible for the 
degradation of host factors, employing a panel of recombinant viruses deleted for various blocks of 
HCMV genes that are non-essential for replication in vitro (10). These viruses included strain AD169, 
a highly passaged, laboratory-adapted strain that contains a deletion in the UL/b’ region (encoding 20 
canonical genes, UL133-UL150A), frameshifts in RL5A, RL13 and UL131A, and a non-synonymous 
substitution in UL36 that inactivates the ability of pUL36 to bind procaspase-8 and inhibit apoptosis 
(22, 23). MLKL was downregulated by strain Merlin viruses but not by strain AD169, and this was 
confirmed by immunoblotting (Figures 3A-B). This indicated that one or more differences in AD169 
abrogate virus-mediated MLKL degradation. To identify viral factors interacting with MLKL, a SILAC 
immunoprecipitation (IP) was performed in HCMV strain Merlin-infected HFFF-TERTs stably 
expressing MLKL tagged with HA at the C-terminus. pUL36 co-precipitated with MLKL, and this was 
confirmed by a reciprocal IP (Figures 3C-D, Dataset S2). This interaction was further supported by an 
immunofluorescence study showing cytoplasmic co-localisation between MLKL-HA and pUL36 in 
stably expressing HFFF-TERTs (SI Appendix, Figure S2A). To determine whether pUL36 interacts 
with inactive, unphosphorylated MLKL or active, phosphorylated MLKL we re-searched the pUL36-
V5 SILAC IP data (Figure 3D) using a variable phospho-modification. All identified MLKL peptides 
were unphosphorylated, and encompassed all known sites of activating phospho-modifications (SI 
Appendix, Figure S3). This suggests that pUL36 interacts with unphosphorylated MLKL but does not 
exclude an additional interaction with phosphorylated MLKL. 
A series of HFFF-TERT cell lines stably expressing strain Merlin UL36 or each of the individual genes 
in the UL133-UL150A region were next screened to determine whether any other viral protein 
contributed to MLKL degradation. Expression of UL36 was sufficient to reduce the level of MLKL by 
3.7-fold (Figure 3E and SI Appendix, Figures S2B-D). MLKL expression was not modulated more 
than 2-fold by any other proteins in the UL/b’ region. Despite substantial variation in the level of 
expression of some of the viral proteins, this did not correlate with relative MLKL abundance (SI 
Appendix, Figure S2D). pUL36 could be detected from 6 hpi, and was expressed with Tp2 (temporal 
protein profile 2) kinetics, matching the kinetics of MLKL degradation (11) (Figure 3F). Finally, 
infection with strain AD169 or two independent strain Merlin UL36 deletion mutants rescued MLKL, 
suggesting that pUL36 was necessary as well as sufficient for MLKL degradation (Figure 3G). 
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pUL36 protects cells from necroptosis 
Inhibition of caspase-8 during death receptor stimulation shifts extrinsic apoptosis towards the 
necroptotic pathway (24–26). The HCMV UL36-encoded viral inhibitor of caspase-8 activation 
(vICA/pUL36) inhibits apoptosis by binding the pro-domain of caspase-8 and preventing its proteolytic 
activation (23). Inhibition of caspase-8 activation by pUL36 would be predicted to promote necroptosis, 
but this has not been reported. We therefore sought to determine whether Merlin pUL36 additionally 
inhibits necroptosis by degrading MLKL. In vitro, necroptosis can be stimulated by a combination of 
TNFα (T), BV6 (B, an IAP antagonist that sensitises cells to TNFα-induced cell death), and the pan-
caspase inhibitor Z-VAD-fmk (Z) (Figure 4A) (27, 28). Although previous reports have suggested that 
HFFFs are not susceptible to necroptosis due to limiting levels of RIP3 (29), both RIP3 and RIP1 were 
detectable in HFFF-TERTs by proteomics (SI Appendix, Figure S4A). Necroptosis was induced by 
T+B+Z (TBZ) in HFFF-TERTs as well as in immortalised mouse embryonic fibroblasts (MEFs), which 
are highly susceptible to necroptosis (30) and were therefore used as a positive control (Figure 4B). 
Two inhibitors were employed to determine whether the stimulated death pathway was canonical 
MLKL- and RIP3-dependent necroptosis (Figure 1). GSK’872 binds to and inhibits the RIP3 kinase 
domain (31, 32), whereas necrosulfonamide (NSA) inhibits downstream effector functions of MLKL 
via covalent reaction with the Cys86 residue of human but not murine MLKL (19, 33). NSA and 
GSK’872 inhibited TBZ-induced cytotoxicity in HFFF-TERTs, indicating that these cells expressed 
sufficient RIP3 to induce measurable canonical necroptosis (Figure 4B). 
Omoto et al. previously demonstrated that pUL36 does not impact the ability of HCMV strain Towne 
to protect against necroptosis in fibroblasts stably transduced with RIP3 (29). In contrast to this 
conclusion, we found that strain Merlin pUL36 was sufficient to inhibit necroptosis (Figure 4C). The 
two other HCMV-encoded inhibitors of apoptosis, pUL37x1/vMIA (viral mitochondria-localized 
inhibitor of apoptosis) and pUL38 (34, 35), augmented MLKL-dependent necroptosis (as demonstrated 
by complete inhibition by NSA). However, cell death was incompletely inhibited by GSK’872, 
suggesting that a RIP3-independent mechanism might be acting in addition (Figure 4C). Next, 
untransduced, control and UL36-expressing cell lines were treated with TB or TBZ in parallel to assess 
the effect of pUL36 on apoptosis and necroptosis respectively (Figure 4D). Other inhibitors of caspase-
8, including MCMV pM36 and the compound z-VAD-fmk (Z), inhibit death receptor-stimulated 
apoptosis while sensitising cells expressing sufficient levels of RIP3 and MLKL to necroptosis (24–
26). Consistent with these observations, we detected no change in the overall level of cell death in 
untransduced cells when Z was added to TB (Figure 4D left panel leftmost bar and right panel 
leftmost bar). In contrast, pUL36 was able to inhibit apoptotic cell death stimulated by TB, suggesting 
that it was not simply acting as a caspase-8 inhibitor (Figure 4D left panel). Furthermore, in the 
presence of TBZ apoptosis is potently inhibited by the addition of Z, and pUL36 inhibited necroptotic 
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cell death (Figure 4D right panel). Together these data indicate that pUL36 can inhibit both apoptosis 
and necroptosis. 
Finally, infection of HFFFs with HCMV strains Merlin and AD169 for 48 h prior to TBZ stimulation 
suggested that inhibition of MLKL-dependent necroptosis required functional pUL36. Pre-infection 
with Merlin had a slight protective effect on necroptosis, whereas AD169 infection amplified the effect 
of TBZ (Figures 4E-F). Cell death induced by TBZ after infection with HCMV also appeared to have 
a RIP3-independent component, as GSK’872 had little inhibitory effect. 
Substitution of Merlin pUL36 Cys131 abrogates inhibition of necroptosis by abolishing 
MLKL binding and degradation  
Strain Merlin and strain AD169 pUL36 differ by five amino acid residues (SI Appendix, Figure S5), 
including a Merlin Cys131  AD169 Arg131 substitution. This single replacement abrogates inhibition 
of apoptosis, as pUL36 can no longer bind procaspase-8 (23). Five Merlin pUL36 mutants 
corresponding to the five amino acid substitutions between strain Merlin and strain AD169 were 
constructed in order to determine which were important for degradation of MLKL. Only the C131R 
substitution prevented pUL36 from binding and downregulating MLKL (Figure 5A-B). The same 
pUL36 mutant was also unable to protect cells from necroptosis, suggesting that this single residue 
plays a key functional role in inhibition of both apoptosis and necroptosis by pUL36 (Figure 5C). 
DISCUSSION 
Herpesviruses persist lifelong in infected individuals by comprehensive modulation of adaptive and 
innate immunity. Multiple viral proteins are deployed to target host factors for degradation, many very 
early during infection (10). The present study provides a systematic, searchable database that examines 
host protein degradation at 48 h of HCMV strain Merlin infection, approximately 50-66% of the way 
through the lytic replication cycle in HFFFs. In addition to identifying proteins degraded throughout 
the HCMV replication cycle, these data may be particularly useful for identifying which viral protein 
targets a given host factor for degradation. We defined previously the kinetics of expression of the 
majority of canonical HCMV proteins, which can now be compared to the kinetics of host protein 
degradation, from 6 to 48 h post-infection (10, 11). Other mechanisms of host protein degradation that 
are not inhibited by MG132 are also likely to be subverted by HCMV. However, 87-89% of degraded 
proteins were targeted to the proteasome by 24 h post-infection (10).  
The key roles of necroptosis in protecting cell populations against virus infection are highlighted by the 
impressive range of known viral countermeasures. Necroptosis inhibitors are particularly widespread 
amongst herpesviruses, with MCMV and herpes simplex viruses (HSV) types 1 and 2 encoding 
conserved RHIM-domain containing proteins (M45, ICP6 and ICP10, respectively) which compete 
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with host RHIM-domain adaptor proteins such as RIP1 for binding to RIP3 (36–38). The HCMV M45 
ortholog pUL45 does not contain a RHIM-domain and does not inhibit cell death (39). Instead, it had 
been suggested that HCMV targets the necroptotic pathway downstream of RHIM signalling, after 
RIP3-dependent phosphorylation of MLKL, although the mechanism had not been elucidated (29). 
As other viral inhibitors of caspase-8 activation have been shown to sensitise cells to programmed 
necrosis (26, 40), it has been assumed that HCMV pUL36 would have a similar effect, requiring HCMV 
to encode a separate mechanism of necroptosis inhibition in order to evade cell death completely. 
However, although MCMV M36 can sensitise cells to necroptosis (26), the same phenomenon has not 
been demonstrated for HCMV pUL36, which may not be surprising given that both proteins exhibit 
only 19% sequence identity (41). The understanding of why HCMV pUL36 expression can inhibit death 
receptor-stimulated apoptosis instead of stimulating necroptosis as per the action of other inhibitors of 
caspase-8 such as z-VAD-fmk and MCMV M36 (24–26) may have been confounded by the use of cell 
lines that are not susceptible to necroptotic cell death (23). Here, we explain these observations by 
showing that HCMV pUL36 mediates the degradation of MLKL and inhibits necroptosis. In the 
presence of either UL36 expression or HCMV Merlin infection, the level of MLKL protein was 
decreased in cells lysed in either 6M guanidine, RIPA or 2% SDS, and subsequently rescued by the 
addition of MG132. Future work should confirm that high molarity guanidine and high percentage SDS 
do indeed fully solubilise RIPA-insoluble MLKL complexes that arise in cells undergoing necroptosis. 
Previous studies investigating the interaction between HCMV and necroptosis have employed HFFFs 
stably transduced with RIP3 in order to confer susceptibility to necroptosis, which can otherwise be lost 
during cell propagation (29). Using these cells, the authors found that all tested HCMV strains, 
including AD169, were able to inhibit TNFα-stimulated necroptosis, although strain Merlin inhibited 
necroptosis more potently than AD169, consistent with our results (Figure 4E). Furthermore, 
comparison of a WT strain Towne (encoding pUL36 with a cysteine at position 131) with a Towne 
ΔUL36 mutant suggested that pUL36 was necessary for inhibition of apoptosis but not necroptosis (29). 
In addition to mediating cell death, RIP3 has been implicated in NF-kB and inflammasome activation 
and can induce apoptosis when overexpressed (32, 42). It is possible that overexpression of RIP3 has 
off-target effects, which may explain the discrepancy between the previously published work and the 
present study; the experimental setting may clearly influence the outcome observed with pUL36. In 
addition, while the Omoto et al. study suggested that HCMV targets necroptosis downstream of MLKL 
phosphorylation, all MLKL peptides in our pUL36-V5 SILAC IP were unphosphorylated (Figure 3D 
and SI Appendix, Figure S3), suggesting that pUL36 affects the monomeric MLKL pool. However, 
this does not exclude the potential for additional HCMV-mediated direct or indirect mechanisms of 
necroptosis inhibition. Further evidence that results can be dependent on cell type and the presence of 
RIP3 overexpression came from use of the Towne ΔUL36 mutant to show that pUL36 can inhibit 
caspase-independent cell death during late stages of macrophage differentiation (43). This also suggests 
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that pUL36-mediated degradation of MLKL may occur in more than one cell type. The HFFF-TERT 
cell line used in the present study is susceptible to RIP3 and MLKL-dependent canonical necroptosis 
(Figure 4B) and may be an invaluable resource for future studies of viral modulation of cell death. 
Necroptotic activation of MLKL can influence many other cellular processes, including inflammasome 
activation, endosomal trafficking, extracellular vesicle generation and autophagy (44–47). It is therefore 
possible that HCMV-mediated degradation of MLKL may have other consequences for viral 
pathogenesis, including effects on virion assembly, trafficking and cell-to-cell spread.  
Infection of HFFF-TERTs with HCMV prior to TBZ stimulation resulted in induction of a form of cell 
death that was not completely inhibited by GSK’872, which is suggestive of an RIP3-independent but 
MLKL-dependent mechanism (Figure 4E). A similar but less significant effect was observed in cells 
expressing the HCMV apoptosis inhibitors pUL37 and pUL38 (Figure 4C). RIP3-independent 
necroptosis in fibroblasts has been reported previously by others (30) but remains poorly characterised. 
Infection with HCMV strain AD169, which lacks a functional pUL36 protein, sensitised cells to 
necroptosis (Figure 4E), in accord with the observed increase in MLKL protein upon infection with 
viruses deficient in functional pUL36 (Figure 3G). This is likely to be due to IFN-mediated 
upregulation of MLKL (48). Strain Merlin protein pUL36 was able to counteract the effect of 
necroptosis sensitisation, rather than abrogating necroptosis entirely (Figure 4E).  
pUL36 can bind both pro-caspase-8 (23) and MLKL, facilitating potent inhibition of both apoptosis and 
necroptosis. Indeed, these two functions can be inhibited by the same single amino acid substitution 
gained during passage of HCMV in cell culture (22, 23). This suggests that a larger cell death complex 
may form from the caspase-8:FADD:RIP1 FADDosome/Ripoptosome (49–51) and the RIP1:RIP3 
necrosome (17), enabling an interaction between pUL36, caspase-8 and MLKL. Examination of this 
hypothesis, including an investigation of whether binding of pUL36 to caspase-8 is a necessary 
intermediary for binding to MLKL, would be of significant interest to the field. 
HCMV pUL36 and its orthologs belong to the US22 family of herpesvirus proteins, which 
characteristically feature a set of motifs I to IV (41). Cys131, which is found within motif III, is conserved 
within the primate cytomegaloviruses but is replaced by conservative substitutions in rodent 
cytomegalovirus orthologs that do not abrogate apoptosis inhibition. In addition, the MCMV ortholog 
pM36, which displays only 19% sequence similarity to HCMV pUL36 and lacks the region that includes 
Cys131, is still an efficient suppressor of apoptosis (41). This suggests that the Arg131 residue of strain 
AD169 pUL36 may restrict cell death inhibition, as opposed to Cys131 being required for this function.  
Only four drugs are currently available for treating HCMV, all exhibiting significant adverse effects 
and the potential of drug resistance. The identification of a potentially inhibitable interaction between 
a single residue of a viral antagonist and key mediators of both necroptosis and apoptosis may therefore 
be of substantial therapeutic significance. In addition to pUL36-MLKL, other interactions involving 
10 
 
distinct antiviral pathways could be targeted simultaneously to potently inhibit viral replication, for 
example between HCMV pUL145 and the recently identified restriction factor HLTF (10). Moreover, 
our data are likely to identify further proteins that have roles in restricting infection by HCMV or other 
viruses. 
MATERIALS AND METHODS 
Extended materials and methods can be found in the SI Appendix.  
Viral infections 
The required volume of viral stock to achieve the multiplicity of infection (MOI) described in the results 
section was diluted in serum-free Dulbecco’s modified Eagle’s medium (DMEM), mixed gently and 
applied to HFFF-TERTs. Mock infections were performed identically but with DMEM instead of viral 
stock. Time zero was considered the time at which cells first came into contact with virus. Cells were 
incubated with virus for 2 h at 37 °C on a rocking platform, and then the medium was replaced with 
DMEM + 10% FBS. 
Proteomic Screen 
HFFFs-TERTs were infected as described above in biological duplicate at an MOI of 10. At 36 hpi, 10 
µM MG132 or the equivalent volume of DMSO was added to the cells for the last 12 h of infection. 
Samples from the second replicate were digested and analysed with residual samples from the 12 h 
degradation screen from the Nightingale el al. study (10). Methods for whole cell lysate protein 
preparation and digestion, peptide labelling with tandem mass tags, HpRP fractionation, liquid 
chromatography-mass spectrometry and data analysis are discussed in detail in the Nightingale et al. 
study (10) and recapitulated in the SI. 
Immunoblotting 
Cells were lysed, sonicated and clarified by centrifugation, and protein concentration was measured 
using a bicinchoninic acid (BCA) assay. Samples were denatured and reduced, and then the proteins 
were separated by SDS polyacrylamide gel electrophoresis (PAGE), transferred to a polyvinylidene 
difluoride (PVDF) membrane (0.45 µm pore), and probed using the primary and secondary antibodies 
detailed in the SI. Fluorescent signals were detected using the Odyssey CLx Imaging System (LI-COR), 
and images were processed and quantified using Image Studio Lite V5.2 (LI-COR). 
Plasmid construction and transduction 
Lentiviral expression vectors encoding MLKL-HA, the V5-tagged viral proteins pUL36 and pUL133-
pUL150A and controls, were synthesised by PCR amplification of the genes and cloning them into 
Gateway vectors (52). V5-tagged UL36 point mutants were generated by PCR site-directed 
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mutagenesis. The primers and templates used are described in the SI. Stable cell lines were generated 
by transduction with lentiviruses produced via the transfection of HEK293T cells with lentiviral 
expression vectors and helper plasmids.  
Immunoprecipitation 
Cells were harvested in lysis buffer, tumbled on a rotator and then clarified by centrifugation and 
filtration. After incubation with immobilised mouse monoclonal anti-V5 or anti-HA agarose resin, 
samples were washed and then subjected either to immunoblotting or mass spectrometry (see SI). 
Cell death assays 
For assays in the absence of infection, 96-well plates were seeded with HFFF-TERTs or immortalised 
MEFs and incubated for 24 h. Cells were incubated for 18 h with 30 ng/ml TNFα, 5 µM BV-6 and/or 
25 µM z-VAD-fmk in the presence or absence of 0.5 µM necrosulfonamide (NSA) or 1.5 µM GSK’872, 
or DMSO alone (control). Half of the control cells were lysed to measure lactate dehydrogenase (LDH) 
release from maximally lysed cells. The other half were used to measure background LDH release from 
live, untreated cells. LDH release was measured using the CytoTox 96® Non-Radioactive Cytotoxicity 
Assay. Average absorbance values derived from culture medium alone were subtracted from each 
absorbance value from experimental wells. For assays in the presence of infection, HFFF-TERTs were 
seeded into 96-well plates, incubated for 24 h, and infected with HCMV (MOI = 5). The medium was 
changed 48 h after infection to stimulate necroptosis as described above. 
Data and materials availability statement 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
(http://www.proteomexchange.org/) via the PRIDE partner repository (53) with the dataset identifier 
PXD017279. All materials described in this manuscript, and any further details of protocols employed, 
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FIGURES AND FIGURE LEGENDS 
 
 
Figure 1. The necroptosis pathway and mechanism of action of small molecule necroptosis 
inhibitors. Two inhibitors of the necroptotic pathway were utilised in this study: GSK’872, which 
inhibits RIP3 kinase activity (31, 32), and necrosulfonamide (NSA), which inhibits downstream effector 









Figure 2. Identification of proteins targeted for degradation by HCMV at 48 hpi. (A) Schematic 
of the experimental method, conducted in biological duplicate. Cellular lysates from the second 48 h 
biological replicate were analysed simultaneously with residual lysates from the 12 h degradation screen 
in the Nightingale et al. study (10), facilitating a direct comparison (SI Appendix, Figure S1A). 
Peptides from each sample were labelled with tandem mass tags and analysed by MS3 mass 
spectrometry. (B) Scatterplots of human proteins quantified at 48 hpi in one or both replicates, showing 
averaged ratios. P-values were estimated using significance B values, then corrected for multiple 
hypothesis testing (54). K-means clustering suggested there were at least nine different patterns of 
protein expression across the samples (Dataset S1C and SI Appendix, Figure S1B). (C) Overlap 
between early degradation data from the Nightingale et al. study (using either stringent or sensitive 
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statistical criteria) (10) and 48 h degradation data presented in this study. (D) Examples of the seven 
proteins degraded with high confidence both early and late during infection. MLKL was only quantified 
in one replicate. Error bars: range. P-values were calculated as described in (B). *p<0.05, **p<0.001, 
***p<1×10-7. Additional proteins were likely to have been degraded both early and late during infection 
(Dataset S1 and SI Appendix, Figure S1A), but did not pass the stringent filtering criteria used at one 
or other of the time points. (E) Examples of the 37 proteins degraded at 48 h that were not confidently 
degraded at early time points. These comprised: (i) proteins not degraded at early time points (shown 
in this figure), (ii) proteins that were insufficiently degraded at early time points to pass filtering criteria, 
and (iii) proteins not quantified in the Nightingale et al. study (10). Additional examples and the 































Figure 3. HCMV strain Merlin pUL36 is necessary and sufficient to degrade MLKL. (A) Relative 
abundance of MLKL from a proteomic screen of >250 proteins published in the Nightingale et al. study 
(10). HFFF-TERTs were infected with strain Merlin (WT1), WT1 that lacked UL16 and UL18 (WT2), 
one of six block-deletion viruses derived from WT1 or WT2, or strain AD169 (MOI = 10, 72 h 
infection). A z-score of >5 was considered significant. (B) Immunoblot confirming that MLKL is 
downregulated by strain Merlin but not by strain AD169 (MOI = 5, 48 h infection, cells lysed in RIPA 
buffer). MLKL was similarly downregulated in cells lysed in 2% SDS (SI Appendix, Figure S2E). 
This was consistent with the observed MLKL downregulation in cells lysed with 6 M guanidine for 
proteomic experiments (Figure 2), and indicated that MLKL was likely degraded as opposed to being 
translocated to RIPA-insoluble membrane-associated complexes. (C) SILAC immunoprecipitation of 
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C-terminally HA-tagged MLKL or control in the presence of strain Merlin infection (MOI = 3, 24 h 
infection in the presence of 10 µM MG132 for the final 12 h). Proteins enriched >5-fold are shown. P-
values were estimated using the method of significance A and corrected for multiple hypothesis testing 
(54). (D) SILAC immunoprecipitation of C-terminally V5-tagged pUL36 or control in the presence of 
10 µM MG132 for 12 h. Proteins that were enriched >5-fold are shown, and p-values were estimated 
as described in (C). (E) Immunoblot showing that pUL36 is sufficient to downregulate MLKL. A series 
of HFFF-TERT cell lines stably expressing genes in the UL133-150A region were lysed in RIPA buffer 
and analysed by immunoblotting. Confirmation of viral protein expression was achieved by 
immunoblotting or mass spectrometry (55) (Dataset S3D and SI Appendix, Figure S2B), except for 
pUL136, which was not detected by either method. MLKL was similarly downregulated by pUL36 in 
cells lysed in 2% SDS (SI Appendix, Figure S2F, as shown during HCMV infection in Figure S2E). 
(F) Temporal profile of strain Merlin pUL36 in whole-cell lysates harvested at different times over the 
whole course of infection, from the Weekes et al. study (11). (G) Immunoblot showing that pUL36 is 
necessary for downregulation of MLKL (MOI = 5, 24 h infection). Cells were infected with WT strain 
Merlin (Merlin*), a version of Merlin in which intact genes UL128 and RL13 are under tet regulation 
(Merlin**), two UL36 deletion viruses derived from Merlin**, or strain AD169. ΔUL36ex2 has a 
deletion in exon 2. Right panel: the relative amount of MLKL normalised to GAPDH. Overall this data 






Figure 4. Role of MLKL degradation in HCMV infection. (A) Schematic of the necroptosis assay, 
which was performed in biological triplicate conducted in parallel and repeated in two or three 
completely independent experiments. Cytotoxicity was quantified by measuring lactate dehydrogenase 
(LDH) release using the CytoTox 96® Non-Radioactive Cytotoxicity Assay (Promega). Cytotoxicity 
was calculated as a percentage of 100% lysis (from untreated cells lysed with lysis buffer) after 
subtraction of background LDH release from live cells. To stimulate apoptosis, cells were treated with 
TB instead of TBZ. (B) TBZ induces MLKL- and RIP3-dependent necroptosis, which was inhibitable 
by GSK’872 in HFFF-TERTs and MEFs. NSA inhibited necroptosis in HFFF-TERTs but not MEFs, 
likely because NSA does not inhibit murine forms of MLKL (19). Error bars show standard error of the 
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mean (SEM). P-values were estimated using a two-tailed t-test (n=3). ***p < 0.001, ****p < 0.0001. 
Data are representative of three independent experiments. To dissect fully the conditions of this assay, 
stimulation with each of T, B and Z alone or in combination was examined in the presence or absence 
of inhibitors (SI Appendix, Figures S4B-C). HFFFs were insensitive to T or Z alone, TZ or BZ. Cell 
death was stimulated by B alone in the absence of death receptor stimulation, an effect that has been 
observed in other cell types (56) (SI Appendix, Figure S4B). The cell death initiated by BV6 was 
MLKL- and RIP3-independent, but also caspase-8-dependent (inhibited by the addition of Z), 
suggesting that BV6 alone was not responsible for the necroptotic cell death observed in the TBZ 
condition (SI Appendix, Figures S4B-C). Collectively, these results suggest that only in the presence 
of TBZ was cell death dependent on MLKL and RIP3. (C) pUL36 is sufficient to inhibit necroptosis in 
stably transduced HFFF-TERTs treated with TBZ ± inhibitors. In addition to untransduced cells, two 
control vectors were employed. ‘Ctrl’ cells were transduced with a vector containing a short, 
randomised DNA sequence. pUL24 was included as a control HCMV tegument protein that has a 
similar size to pUL36 but lacks any known role in cell death. Error bars: SEM. P-values were estimated 
using a two-tailed t-test (n=3). **p < 0.01, ***p < 0.001, ****p < 0.0001. Data are representative of 
two independent experiments. (D) pUL36 inhibits both apoptosis and necroptosis. Untransduced, 
control or pUL36-expressing HFFF-TERTs were treated for 18 h with either TB or TBZ to stimulate 
apoptosis or necroptosis, respectively, in the presence or absence of NSA or GSK’872. Error bars: SEM. 
P-values were estimated using a two-tailed t-test (n=3). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 
0.0001. Data are representative of two independent experiments. (E) Functional pUL36 was required 
for inhibition of necroptosis, comparing 48 h mock, Merlin or AD169 infection (MOI = 5) in HFFF-
TERTs subsequently stimulated with TBZ ± inhibitors for 18 h. Baseline cytotoxicity in untreated cells 
was not subtracted from the other values and is shown as a separate yellow bar. Error bars: SEM. P-
values were estimated using a two-tailed t-test (n=3). *p < 0.05, ***p < 0.001, ****p < 0.0001. Data 
are representative of two independent experiments. (F) MLKL-dependent cytotoxicity was calculated 
from the difference between % cytotoxicity (TBZ alone) versus (TBZ+NSA), shown by the double-






Figure 5. Substitution of Cys131 in strain Merlin pUL36 abrogates binding to and degradation of 
MLKL, and inhibition of necroptosis. (A) Immunoblot showing that downregulation of MLKL is 
dependent on the pUL36 Cys131 residue. HFFF-TERTs were stably transduced with the indicated C-
terminally V5-tagged UL36 constructs. Individual point mutations corresponding to the five amino acid 
substitutions between strain Merlin and strain AD169 pUL36 are shown above the blot and detailed in 
Figure S5 (SI Appendix). (B) Interaction between pUL36 and MLKL is dependent on pUL36 Cys131, 
shown by a V5 co-IP in the cell lines described in (A). Immunoblots were probed with anti-V5, anti-
MLKL and anti-GAPDH antibodies. (C) Percentage cytotoxicity of cell lines described in (A) that were 
treated with TBZ ± NSA or GSK’872. Error bars: SEM. P-values were estimated using a two-tailed t-
test (n=3). *p<0.05, **p < 0.01, ***p < 0.001, ****p< 0.0001. Data are representative of two 
independent experiments. Low-level variation in sensitisation to necroptosis was observed between the 
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Supplementary Information Text 
Materials and Methods 
Cells and cell culture 
All fibroblast cell lines generated in this paper were derived from human foetal foreskin fibroblasts 
immortalised with human telomerase (HFFF-TERTs) (1). HFFF-TERTs have been tested at regular 
intervals since isolation to confirm that human leukocyte antigen (HLA) and MHC Class I 
Polypeptide-Related Sequence A (MICA) genotypes, cell morphology and antibiotic resistance are 
unchanged. HFFF-Tets (used for growing tet-regulated viruses) additionally constitutively 
expressed the tetracycline (tet) repressor. Mouse embryonic fibroblasts (MEFs) immortalised with 
SV40 large T antigen were kindly provided by Dr Evan Reid (University of Cambridge) and are 
described in the Allison et al. study (2). HEK293T cells used for generation of lentivirus were 
obtained as a gift from Professor Paul Lehner (University of Cambridge). All cells were grown at 
37 °C in 5 % v/v CO2 in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with foetal 
bovine serum (FBS: 10% v/v), and 100 IU/ml penicillin / 0.1 mg/ml streptomycin 
(DMEM/FBS/PS). For SILAC immunoprecipitations (IPs), cells were grown for seven passages in 
SILAC DMEM (Gibco), which was supplemented with 10% dialysed FBS (Gibco), 
penicillin/streptomycin, 280 mg/l L-proline (Sigma-Aldrich), and either medium (Arg 6, Lys 4) or 
heavy (Arg 10, Lys 8) amino acids (CK Isotopes) at 50 mg/ml.  
Viruses 
The genome sequence of HCMV strain Merlin (GenBank accession AY446894) is designated the 
reference HCMV sequence (RefSeq accession NC_006273.2) by the National Center for 
Biotechnology Information (3, 4). A recombinant version (RCMV1111) of this strain was derived 
by transfection of a sequenced BAC clone (4). RCMV1111 contains point mutations in two genes 
(RL13 and UL128) that enhance replication in fibroblasts (4). The block HCMV deletion mutants 
are described in the Nightingale et al. study (5). The AD169-GFP virus (RCMV288) is described 
in the McSharry et al. study (1). RCMV1502 is an RCMV1111 recombinant that has tet-operators 
5’ to the RL13 and UL128 coding sequences (Merlin-RL13tetO-UL128tetO,) and is described in the 
Stanton et al. study (4). UL36 deletion mutants were generated by recombineering RCMV1502 (4). 
Two deletion mutants were generated, one lacking the whole UL36 coding sequence (ΔUL36; 
RCMV2288), and the other lacking the second UL36 exon (ΔUL36ex2; RCMV2289). Virus stocks 





et al. study (6). Whole-genome consensus sequences of passage 1 of each RCMV were determined 
using the Illumina platform as described previously (7). 
Viral infections 
The required volume of viral stock to achieve the multiplicity of infection (MOI) described in the 
results section was diluted in serum-free DMEM, mixed gently and applied to HFFF-TERTs. Mock 
infections were performed identically but with DMEM instead of viral stock. Time zero was 
considered the time at which cells first came into contact with virus. Cells were incubated with 
virus for 2 h at 37 °C on a rocking platform, and then the medium was replaced with DMEM/FBS. 
Proteomic Screen 
The 48 h degradation screen in this paper was performed in biological duplicate. Cellular lysates 
from the second 48 h biological replicate were analysed simultaneously with residual lysates from 
the 12 h degradation screen in the Nightingale et al. study (5), thus facilitating a direct comparison. 
Infection 
In Experiment 1, 3×106 HFFF-TERTs were plated in DMEM/FBS/PS in 75 cm2 flasks. After 24 
h, the medium was replaced by serum-free DMEM containing 4 μg/ml dexamethasone, which has 
been shown to improve infection efficiency (8, 9). After a further 24 h, the medium was removed 
and the cells were infected as described above at an MOI of 10. At 36 hours post-infection (hpi), 
10 µM MG132 (Merck) or the equivalent volume of DMSO (Sigma-Aldrich) was added to the 
cells. In Experiment 2, 8×105 HFFF-TERTs were seeded into 25 cm2 flasks, and then treated as in 
Experiment 1. 
Whole Cell Lysate Protein Digestion 
Methods for whole cell lysate protein preparation and digestion, peptide labelling with tandem mass 
tags, HpRP fractionation, liquid chromatography-mass spectrometry and data analysis are 
discussed in detail in the Nightingale et al. study (5), and are recapitulated below including 
modifications for the present study. 
At 48 hpi, cells were washed twice with PBS, and 500 µl lysis buffer was added (6 M guanidine/50 
mM HEPES pH 8.5). Cell lifters (Corning) were used to scrape the cells into lysis buffer, which 
was then removed to an eppendorf tube, vortexed extensively and sonicated. Cell debris was 





From this point onward, lysates from the second biological replicate (Experiment 2) were treated 
identically to residual lysates from a 12 h degradation screen that we performed previously (5). 
Dithiothreitol (DTT) was added to a final concentration of 5 mM and incubated at room temperature 
for 20 mins. Cysteine residues were alkylated with 15 mM iodoacetamide and incubated for 20 min 
at room temperature in the dark. Excess iodoacetamide was quenched with DTT for 15 mins. 
Samples were diluted with 200 mM HEPES pH 8.5 to 1.5 M guanidine followed by digestion at 
room temperature for 3 h with LysC protease at a 1:100 protease-to-protein ratio. Samples were 
further diluted with 200 mM HEPES pH 8.5 to 0.5 M guanidine. Trypsin was then added at a 1:100 
protease-to-protein ratio followed by overnight incubation at 37°C. The reaction was quenched 
with 5% formic acid and centrifuged at 21,000 g for 10 min to remove undigested protein. Peptides 
were subjected to C18 solid-phase extraction (SPE, Sep-Pak, Waters) and vacuum-centrifuged to 
near-dryness. 
Peptide Labelling with Tandem Mass Tags 
In preparation for TMT labelling, desalted peptides were dissolved in 200 mM HEPES pH 8.5. 
Peptide concentration was measured by microBCA (Pierce), and 25 µg of peptide was labelled with 
TMT reagent. TMT reagents (0.8 mg, Thermo Scientific) were dissolved in 43 µl anhydrous 
acetonitrile and 3 µl were added to each peptide sample at a final acetonitrile concentration of 30% 
(v/v). Samples were labelled as follows: Experiment 1: 48 h mock (TMT 128N), 48 h infection 
(TMT 129N), 48 h infection / MG132 (TMT 130C). Experiment 2: 12 h mock (TMTpro 126), 12 
h infection (TMTpro 127C), 12 h infection / MG132 (TMTpro 128N), 48 h mock (TMTpro 131C), 
48 h infection (TMTpro 132C), 48 h infection / MG132 (TMTpro 133N). Following incubation at 
room temperature for 1 h, the reaction was quenched with hydroxylamine to a final concentration 
of 0.5% (v/v). TMT-labelled samples were combined at a 1:1:1 ratio (Experiment 1) or 1:1:1:1:1:1 
ratio (Experiment 2). The sample was vacuum-centrifuged to near dryness and subjected to C18 
SPE (Sep-Pak, Waters). An unfractionated single-shot was analysed initially to ensure similar 
peptide loading across each TMT channel, thus avoiding the need for excessive electronic 
normalisation. In Experiment 1, data from the single-shot experiment was analysed with data from 
the corresponding fractions to increase the overall number of peptides quantified. In Experiment 
2, data from 13 fractions were used in the analysis. Normalisation is discussed in ‘Data Analysis’ 





Offline HpRP Fractionation 
TMT-labelled tryptic peptides were subjected to HpRP fractionation using an Ultimate 3000 RSLC 
UHPLC system (Thermo Fisher Scientific) equipped with a 2.1 mm internal diameter (ID) x 25 cm 
long, 1.7 µm particle Kinetix Evo C18 column (Phenomenex). Mobile phase consisted of A: 3% 
acetonitrile (MeCN), B: MeCN, and C: 200 mM ammonium formate pH 10. Isocratic conditions 
were 90% A/10% C, and C was maintained at 10% throughout the gradient elution. Separations 
were conducted at 45 °C. Samples were loaded at 200 µl/minute for 5 min. The flow rate was then 
increased to 400 µl/minute over 5 minutes, after which the gradient elution proceeded as follows: 
0-19% B over 10 minutes, 19-34% B over 14.25 minutes, 34-50% B over 8.75 minutes, followed 
by a 10 min wash at 90% B. UV absorbance was monitored at 280 nm and 15 s fractions were 
collected into 96 well microplates using the integrated fraction collector. Fractions were 
recombined orthogonally in a checkerboard fashion, combining alternate wells from each column 
of the plate into a single fraction, and commencing combination of adjacent fractions in alternating 
rows. Wells were excluded prior to the start or after the cessation of elution of peptide-rich 
fractions, as identified from the UV trace. This yielded two sets of 12 combined fractions, A and 
B, which were dried in a vacuum centrifuge and resuspended in 10 µl MS solvent (4% MeCN/5% 
formic acid) prior to LC-MS3. 12 set ‘A’ fractions were used for MS analysis for Experiment 1 
and 12 set ‘A’ and one set ‘B’ fractions were used for Experiment 2. 
LC-MS3 
For Experiment 1, mass spectrometry data were acquired using an Orbitrap Fusion mass 
spectrometer (Thermo Fisher Scientific, San Jose, CA). Peptides were separated using a Proxeon 
EASY-nLC 1000 LC pump equipped with a 75 μm inner diameter microcapillary column packed 
with 0.5 cm of Magic C4 resin (5 μm, 100 Å, Michrom Bioresources) followed by ∼20 cm of 
GP118 resin (1.8 μm, 120 Å, Sepax Technologies). Peptides were separated using a 3 hr gradient 
of 6-30% acetonitrile in 0.125% formic acid at a flow rate of 300 nL/min. Each analysis used a 
MultiNotch MS3-based TMT method (10, 11). The following settings were used: MS1: 400-1400 
Th, Quadrupole isolation, 120,000 Resolution, 2×105 AGC target, 100 ms maximum injection time, 
ions injected for all parallisable time. MS2: Quadrupole isolation at an isolation width of m/z 0.5, 
CID fragmentation (NCE 35) with ion trap scanning out in rapid mode from m/z 350, 4000 AGC 
target, 150 ms maximum injection time, in centroid mode. MS3: In Synchronous Precursor 
Selection mode, the top 10 MS2 ions were selected for HCD fragmentation (NCE 55) and scanned 
in the Orbitrap at 60,000 resolution with an AGC target of 5×104 and a maximum accumulation 





had a target time of 3 s. Dynamic exclusion was set to +/- 7 ppm for 90 s. MS2 fragmentation was 
trigged on precursors 5×103 counts and above. 
For Experiment 2, mass spectrometry data were acquired using an Orbitrap Lumos (Thermo Fisher 
Scientific, San Jose, CA). An Ultimate 3000 RSLC nano UHPLC equipped with a 300 µm ID x 5 
mm Acclaim PepMap µ-Precolumn (Thermo Fisher Scientific) and a 75 µm ID x 50 cm 2.1 µm 
particle Acclaim PepMap RSLC analytical column was used. Loading solvent was 0.1% formic 
acid (FA), analytical solvent A: 0.1% FA and B: 80% MeCN + 0.1% FA. All separations were 
carried out at 40°C. Samples were loaded at 5 µl/min for 5 min in loading solvent before beginning 
the analytical gradient. The following gradient was used: 3-7% B over 3 min, 7-37% B over 173 
min, followed by a 4 min wash at 95% B and equilibration at 3% B for 15 min. Each analysis used 
a MultiNotch MS3-based TMT method (10, 11). The following settings were used: MS1: 380-1500 
Th, 120,000 Resolution, 2×105 automatic gain control (AGC) target, 50 ms maximum injection 
time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, CID fragmentation (normalised 
collision energy (NCE) 34) with ion trap scanning in turbo mode from m/z 120, 1.5×104 AGC 
target, 120 ms maximum injection time. MS3: In Synchronous Precursor Selection mode the top 
10 MS2 ions were selected for HCD fragmentation (NCE 45) and scanned in the Orbitrap at 60,000 
resolution with an AGC target of 1×105 and a maximum accumulation time of 150 ms. Ions were 
not accumulated for all parallelisable time. The entire MS/MS/MS cycle had a target time of 3 s. 
Dynamic exclusion was set to ± 10 ppm for 70 s. MS2 fragmentation was trigged on precursors 
5×103 counts and above. 
Immunoblotting 
For the majority of immunoblots in this study, cells were lysed in RIPA buffer (Cell Signalling 
Technology) containing cOmplete EDTA-free Protease Inhibitor Cocktail (Roche) for 15 minutes 
at 4°C. For Figures S2E and S2F, cells were lysed in 2% SDS in PBS supplemented with 2.5 U/µl 
benzonase (Sigma) for 30 minutes at 37°C. Supernatants were sonicated and clarified by 
centrifugation at 14,000 g for 10 minutes. A Bicinchoninic Acid (BCA) assay (Pierce) was used to 
measure protein concentration according to the manufacturer’s instructions. Samples were 
denatured and reduced with 6× Protein Loading Dye (375 mM Tris pH 6.8, 12% SDS, 30% 
glycerol, 0.6 M DTT, 0.06% bromophenol blue) for 5 minutes at 95°C. 40 µg (except Figure 5A; 
50 µg and Figure S2E; 20 µg) of protein was separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) using Mini-PROTEAN TGX precast gels (Bio-Rad), then transferred to 
polyvinylidene difluoride (PVDF) membranes (0.45 µm pore) using the Bio-Rad Trans-Blot 





14993S, 1:1000), anti-IE1/2 (Abcam, ab53495, 1:1000), anti-GAPDH (R&D Systems, MAB5718, 
1:10,000), anti-V5 (Invitrogen, R960-25, 1:2000). Secondary antibodies used were IRDye 680RD 
goat anti-mouse (LI-COR, 925-68070, 1:10,000) and IRDye 800CW goat anti-rabbit (LI-COR, 
925-32211, 1:10,000). Fluorescent signals were detected using the Odyssey CLx Imaging System 
(LI-COR), and images were processed and quantified using Image Studio Lite V5.2 (LI-COR). 
Plasmid construction 
Generation of lentiviral expression vectors 
cDNA was generated from HFFF-TERTs by reverse transcription of RNA using an RNeasy Mini 
Kit (Qiagen) followed by GoScript Reverse Transcriptase (Promega) according to the 
manufacturer’s protocol. To generate an expression construct for MLKL-HA, primers were 
designed to recognise the 3’ and 5’ ends of the MLKL gene and contained flanking Gateway attB 
sequences to facilitate cloning into pDONR223 using the Gateway system (Thermo Scientific). The 
reverse primer additionally contained a 6 bp linker region, followed by the coding sequence for an 
HA tag and a stop codon (Dataset S3A). 
For expression of the V5-tagged viral genes, recombinant adenovirus vectors (RAds) were used as 
a template as described previously (9). Each template expressed a C-terminally V5-tagged gene 
under the control of the HCMV major immediate early promoter, with a 6 bp linker region between 
the end of the gene and the tag. To amplify genes from the RAds, primers were designed to 
recognise the 3’ end of the HCMV promoter (forward ‘GAW-CMVp-F’) and the 3’ end of the V5 
tag (reverse ‘attB2-V5-R’) (Dataset S3A). Both primers had flanking Gateway attB sequences. 
Spliced UL150A was synthesized as double-stranded DNA fragment (gBlocks®, Integrated DNA 
Technologies) comprising the viral gene succeeded by a 6 bp linker region, the coding sequence 
for the V5 tag and then the stop codon, and Gateway attB sequences. 
PCR amplification of MLKL-HA and the viral genes was achieved using PfuUltra II fusion HS 
DNA polymerase (Agilent). PCR products were subsequently purified using a QIAquick Gel 
Extraction Kit (Qiagen), cloned into the pDONR223 entry vector, and then into the lentiviral 
destination vector pHAGE-pSFFV (described in the Nightingale et al. study (5)) (12). The sequence 
of MLKL was confirmed as the long, necroptotic isoform and shown to contain two non-disease-
causing natural variants (S52T and M169L); this and the confirmed sequences of HCMV genes 
used in this study are shown in Dataset S3B. The UL36 gene sequence contains a single intron. 





HFFF-TERTs and sequencing of the cDNA (Dataset S3B). The pHAGE-SFFV control vector 
contains a short randomized DNA sequence (5). 
All constructed plasmids were transformed into Alpha-Select Silver Efficiency Competent E. coli 
cells (Bioline) and selected on antibiotic-containing LB agar plates (pDONR223; spectinomycin, 
pHAGE-pSFFV; ampicillin). 
PCR site-directed mutagenesis to generate UL36 point mutants 
In the first round of PCR, two pairs of primers were used in two separate PCRs using strain Merlin 
UL36-V5 in the pDONR223 vector as a template. In the first reaction, reverse PCR primers 
encompassing each of the point mutants were combined with the UL36 attB1 fwd primer (Dataset 
S3C). In the second reaction, forward PCR primers encompassing each of the point mutants were 
combined with the UL36 V5 attB2 rev primer (Dataset S3C). A second round of PCR joined the 
two halves of UL36 by using the UL36 attB1 fwd and UL36 V5 attB2 rev primers. Five resulting 
PCR products encoding each of the different point mutants flanked by attB sites were cloned into 
pDONR223 and then pHAGE-pSFFV by Gateway cloning, and the sequences were confirmed. 
Stable cell line production 
Lentiviral particles were generated through transfection of HEK293T cells with the lentiviral 
expression vector and two helper plasmids (VSVg and pCMV.DR8.91, both kindly provided by 
Professor Paul Lehner), using TransIT-293 (Mirus) according to the manufacturer’s instructions. 
Viral supernatant was harvested 48 h after transfection and diluted to achieve ~30% transduction 
of target cells, and debris was removed using a 0.22 µM filter (Millipore). 48 h after transduction, 
cells were subjected to antibiotic selection. Expression of the viral proteins pUL36 and pUL133-
pUL150A was confirmed by immunoblotting for the V5 tag or IP-MS (9) (see 
‘Immunoprecipitation’) (Dataset S3D). 
Immunoprecipitation 
Cells were harvested in lysis buffer (50 mM Tris pH 7.5, 300 mM NaCl, 0.5% (v/v) NP40, 1 mM 
DTT and cOmplete EDTA-free Protease Inhibitor Cocktail (Roche)), tumbled on a rotator for 15 
minutes at 4 °C, and then centrifuged at 16,100 g for 15 minutes at 4 °C. Lysates were clarified by 
filtration through a 0.7 µm filter and incubated for 3 h with immobilised mouse monoclonal anti-






Sample preparation for proteomic analysis 
Confirmation of expression of viral proteins and analysis of SILAC IP data were achieved by using 
LC-MS/MS. Proteins bound to the resin were eluted twice with 200 µl of 250 µg/ml V5 (Alpha 
Diagnostic International) or HA (Sigma-Aldrich) peptide in PBS at 37 °C for 30 minutes with 
agitation. For SILAC-labelled samples, the medium- and heavy-labelled samples were then 
combined. Proteins were precipitated with 20% Trichloroacetic acid (TCA), washed once with 10% 
TCA, washed three times with cold acetone and dried to completion. The proteins were then 
digested in digestion buffer (50 mM Tris-HCl pH 8.5, 10% acetonitrile, 1 mM DTT, 10 µg/ml 
trypsin) and incubated overnight at 37 °C with agitation. The digestion reaction was quenched with 
50% FA, and the peptides were subjected to C18 solid-phase extraction and dried in a centrifugal 
vacuum. Samples were resuspended in 4% acetonitrile / 5% FA in HPLC grade water and analysed 
by mass spectrometry on the Orbitrap Lumos as described below. 
LC-MS/MS for IP experiments 
Mass spectrometry data were acquired using an Orbitrap Fusion mass spectrometer (Thermo Fisher 
Scientific, San Jose, CA). Peptides were separated using an Ultimate 3000 RSLC nano UHPLC 
equipped with a 300 µm ID x 5 mm Acclaim PepMap µ-Precolumn (Thermo Fisher Scientific) and 
a 75 µm ID x 50 cm 2.1 µm particle Acclaim PepMap RSLC analytical column. Peptides were 
separated using a 3 hr gradient of 3-37% acetonitrile in 0.125% formic acid at a flow rate of 250 
nL/min. The following settings were used: MS1: 350-1500 Th, Quadrupole isolation, 120,000 
Resolution, 2×105 AGC target, 50 ms maximum injection time, ions injected for all parallisable 
time. MS2: Quadrupole isolation at an isolation width of m/z 0.7, HCD fragmentation (NCE 34) 
with ion trap scanning out in rapid mode from m/z 120, 10000 AGC target, 250 ms maximum 
injection time, in centroid mode. Dynamic exclusion was set to +/- 10 ppm for 25 s. MS2 
fragmentation was trigged on precursors 5×103 counts and above. 
Sample preparation for immunoblotting 
Proteins bound to the resin were eluted once with 40 µl 2.5 mg/ml V5 or HA peptide at 37 °C for 
1 hour with agitation. Eluted proteins were reduced with 6× Protein Loading Dye (Tris 375 mM 
pH 6.8, 12% SDS, 30% glycerol, 0.6M DTT, 0.06% bromophenol blue) at 95 °C for 5 minutes 
prior to separation by SDS-PAGE as described above. For the input blot, 2% of the original lysates 







1.2×105 HFFF-TERTs were seeded onto 13 mm coverslips (VWR) in a 24-well plate and incubated 
overnight. Coverslips were washed in the well three times with PBS and then fixed with 4% 
paraformaldehyde Fixation Buffer (Bio-Rad) for 20 minutes at room temperature. Two more 
washes with PBS were followed by permeabilisation in 0.1% (v/v) Triton® X-100 (Thermo) / 2% 
(v/v) FBS in PBS for 4 minutes. Coverslips were then washed twice in each of blocking buffer 
(10% (v/v) FBS in PBS), PBS and ultrapure water, before blocking for 1 h. The primary antibodies 
were diluted in blocking buffer and incubated with the coverslips overnight at 4 °C. Coverslips 
were then washed in blocking buffer, PBS and water as before, and then incubated with secondary 
antibody in blocking buffer for 1 h. Coverslips were washed again as before, incubated with 1 
µg/ml DAPI (Thermo Scientific) in water and washed again before mounting on slides with 
ProLong™ Gold antifade reagent (Thermo Scientific). The primary antibodies used were anti-HA 
(Cell Signalling Technology, 3724, 1:50) and anti-V5 (Thermo, MA5-15253, 1:1000). The 
secondary antibodies used were anti-mouse Alexa Fluor® 488 (Cell Signalling Technology, 4408S, 
1:300) and anti-rabbit Alexa Fluor® 647 (Thermo, A31573, 1:300). 
Cell death assays 
All experiments were performed in biological triplicate conducted in parallel and repeated in 2 or 
3 completely independent experiments. Input cell numbers and time of stimulation were optimised 
to ensure that sufficient cells died to facilitate quantitation of statistically significant differences 
between cell populations, and resulted in absorbance values within the dynamic range of the plate 
reader. For assays in the absence of infection, 96-well plates were seeded with HFFF-TERTs 
(18,000 cells/well) or immortalised MEFs (6,000 cells/well) then incubated for 24 h. For test cells, 
the medium was changed to DMEM supplemented with 5% v/v FBS, 30 ng/ml TNFα (R&D 
systems), 5 µM BV-6 (Selleckchem), or 25 µM z-VAD-fmk (BD Pharmingen) in the presence or 
absence of 0.5 µM necrosulfonamide (NSA, Merck) or 1.5 µM GSK’872 (Cayman Chemical) for 
18 h. Each compound was solubilised in DMSO, and DMSO was added such that its final 
concentration in each experimental condition was the same. For control cells, the medium was 
changed to DMEM supplemented with an equivalent concentration of DMSO. 45 mins prior to 
harvest, half of the control cells were treated with 10 µl 10X Lysis Solution (Promega) to observe 
lactate dehydrogenase (LDH) release from maximally lysed cells. The other half were used to 
measure background LDH release from live, untreated cells. Supernatants were harvested and the 
release of LDH was measured using the CytoTox 96 Non-Radioactive Cytotoxicity Assay 





each absorbance value from experimental wells. For assays in the presence of infection, HFFF-
TERTs (14,000 cells/well) were seeded into 96-well plates, incubated for 24 h, and infected with 
HCMV (MOI = 5). 48 h after infection, the medium was changed as described above to generate 
populations of cells stimulated for necroptosis, or control cells. 
Quantification and Statistical Analysis 
Data Analysis 
Mass spectra were processed using a Sequest-based software pipeline for quantitative proteomics, 
‘‘MassPike’’, through a collaborative arrangement with Professor Steven Gygi’s laboratory at 
Harvard Medical School. MS spectra were converted to mzXML using an extractor built upon 
Thermo Fisher’s RAW File Reader library (version 4.0.26). In this extractor, the standard mzxml 
format has been augmented with additional custom fields that are specific to ion trap and Orbitrap 
mass spectrometry and essential for TMT quantitation. These additional fields include ion injection 
times for each scan, Fourier Transform-derived baseline and noise values calculated for every 
Orbitrap scan, isolation widths for each scan type, scan event numbers and elapsed scan times. This 
software is a component of the MassPike software platform and is licensed by Harvard Medical 
School. A combined database was constructed from (a) the human Uniprot database (26th January, 
2017), (b) the HCMV strain Merlin Uniprot database, (c) all additional non-canonical HCMV ORFs 
described by Stern-Ginossar et al. (13), (d) a six-frame translation of HCMV strain Merlin filtered 
to include all potential ORFs of ≥8 amino acids (delimited by stop-stop rather than requiring ATG-
stop) and (e) common contaminants such as porcine trypsin and endoproteinase LysC. ORFs from 
the six-frame translation (6FT-ORFs) were named as follows: 6FT_Frame_ORFnumber_length, 
where Frame is numbered 1-6, and length is the length in amino acids. The combined database was 
concatenated with a reverse database composed of all protein sequences in reversed order. Searches 
were performed using a 20 ppm precursor ion tolerance. Fragment ion tolerance was set to 1.0 Th. 
TMT tags on lysine residues and peptide N termini (Experiment 1: 229.162932 Da; Experiment 
2: 304.2071) and carbamidomethylation of cysteine residues (57.02146 Da) were set as static 
modifications, while oxidation of methionine residues (15.99492 Da) was set as a variable 
modification. Where indicated, data were re-searched using phosphorylation (79.96633 Da) of 
serine, threonine or tyrosine residues as an additional variable modification. For SILAC analysis, 
the following variable modifications were used: heavy lysine (8.01420 Da), heavy arginine 
(10.00827 Da), medium lysine (4.02511 Da), and medium arginine (6.02013 Da). SILAC-only 
searches were performed in the same manner, omitting the TMT static modification. To control the 





spectral matches (PSMs) were filtered to an initial peptide-level false discovery rate (FDR) of 1% 
with subsequent filtering to attain a final protein-level FDR of 1%. PSM filtering was performed 
using a linear discriminant analysis, as described previously (14). This distinguishes correct from 
incorrect peptide IDs in a manner analogous to the widely used Percolator algorithm 
(https://noble.gs.washington.edu/proj/percolator/), though employing a distinct machine-learning 
algorithm. The following parameters were considered: XCorr, DCn, missed cleavages, peptide 
length, charge state, and precursor mass accuracy. Protein assembly was guided by principles of 
parsimony to produce the smallest set of proteins necessary to account for all observed peptides 
(algorithm described in (14)). Where all PSMs from a given HCMV protein could be explained 
either by a canonical gene or non-canonical ORF, the canonical gene was picked in preference. In 
a small number of cases, PSMs assigned to a non-canonical or 6FT-ORF were a mixture of peptides 
from the canonical protein and the ORF. This most commonly occurred where the ORF was a 5’-
terminal extension of the canonical protein (thus meaning that the smallest set of proteins necessary 
to account for all observed peptides included the ORFs alone). In these cases, the peptides 
corresponding to the canonical protein were separated from those unique to the ORF, generating 
two separate entries. In a single case, PSM were assigned to the 6FT-ORF 
6FT_6_ORF1202_676aa, which is a 5’-terminal extension of the non-canonical ORF ORFL147C. 
The principles described above were used to separate these two ORFs. Proteins were quantified by 
summing TMT reporter ion counts across all matching peptide-spectral matches using 
’’MassPike’’, as described previously (10). Briefly, a 0.003 Th window around the theoretical m/z 
of each reporter ion was scanned for ions and the maximum intensity nearest to the theoretical m/z 
was used. The primary determinant of quantitation quality is the number of TMT reporter ions 
detected in each MS3 spectrum, which is directly proportional to the signal-to-noise (S:N) ratio 
observed for each ion. Conservatively, every individual peptide used for quantitation was required 
to contribute sufficient TMT reporter ions so that each on its own could be expected to provide a 
representative picture of relative protein abundance (10). An isolation specificity filter with a cut-
off of 50% was additionally employed to minimise peptide co-isolation (10). Peptide-spectral 
matches with poor quality MS3 spectra (a combined S:N ratio of less than 120 (Experiment 1) or 
240 (Experiment 2) across all TMT reporter ions) or no MS3 spectra at all were excluded from 
quantitation. Peptides meeting the stated criteria for reliable quantitation were then summed by 
parent protein, in effect weighting the contributions of individual peptides to the total protein signal 
based on their individual TMT reporter ion yields. Protein quantitation values were exported for 
further analysis in Excel. For protein quantitation, reverse and contaminant proteins were removed, 





equal protein loading across all channels. To combine data from 48 h experiments 1 and 2, 
fractional TMT signals compared to the sum across all three assessed conditions were used. For 
example, for protein PCDHGB5, three fractions were calculated for each experiment: 
mock/(sum(mock,HCMV,HCMV+MG)), HCMV/(sum(mock,HCMV,HCMV+MG)), 
HCMV+MG/(sum(mock,HCMV,HCMV+MG)). Replicate fractions from each experiment were 
averaged for display in figures, and for the purposes of fold change calculation. This effectively 
corrected for differences in the numbers of peptides observed per protein. For the TMT-based 
experiments, both normalised S:N values and fractional TMT signals are presented in Dataset S1 
(‘Data’ worksheet). For proteins only quantified in one replicate, the ’48 h average’ plot in this 
dataset shows the data from the replicate in which the protein was quantified; otherwise, the average 
and range of the two fractional TMT signals. Data are similarly displayed in Figures 2D-E. 
Although peptides were assigned appropriately to HLA-A alleles, it was not possible to assign 
peptides confidently to only two HLA-B or HLA-C alleles, and signal:noise values were further 
summed for each of these alleles to give a single combined result for HLA-B or HLA-C.  
Figure 2 and S1B. K-means clustering was performed using Cluster 3.0 (Stanford University) and 
visualised using Java Treeview (http://jtreeview.sourceforge.net). 
Figure S5. Alignment of pUL36 amino acid sequences with performed using Clustal Omega (15) 
(https://www.ebi.ac.uk/Tools/msa/clustalo/) by EMBL-EBI. 
Statistical analysis 
Figures 2, S1A and S4A. The method of Significance B was used to estimate the p-value that the 
fold downregulation or rescue was significantly different to 1 (16). Values were calculated and 
corrected for multiple hypothesis testing using the method of Benjamini-Hochberg in Perseus 
version 1.5.2.20 (16). 
Figure 3. P-values for enrichment in immunoprecipitations were estimated using the method of 
Significance A and corrected for multiple hypothesis testing in Perseus version 1.5.2.20 (16). 
Figures 4 and 5. P-values were calculated using a Student’s two-sample, two-tailed t-test in R 
version 3.4.1 (17). A Shapiro-Wilk test was used to determine that the data was normally distributed 






Data and materials availability statement 
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium 
(http://www.proteomexchange.org/) via the PRIDE partner repository (18) with the dataset 
identifier PXD017279. All materials described in this manuscript, and any further details of 





































Figure S1. (A) Comparison of 12 and 48 h degradation data for individual proteins. A direct 
contrast can be made between 12 h data and the second 48 h biological replicate, as both samples 
were simultaneously digested into peptides, labelled with TMT reagents and analysed. Data for the 
first 48 h replicate are also shown for comparison. 12 h data were derived by re-analysis of residual 
protein samples from the Nightingale et al. study (5). (i) Four proteins degraded at 48 h but not at 
12 h. (ii) Four proteins degraded at 48 h, but insufficiently degraded at 12 h to pass filtering criteria 
in the Nightingale et al. study (5). P-values are shown above the data for 48 h experiment 2 and 
were derived from ratios generated from averaged data from experiments 1 and 2 using 
Significance B values (Figure 2B) *p<0.05, **p<0.001, ***p<1×10-7. A full list of proteins 
degraded late in infection can be found in Dataset S1, including details of which are also degraded 
early. (B) K-means-based hierarchical cluster analysis of all human proteins quantified (Figure 
2B).  K-means clustering with 1-20 classes was used to assess the summed distance of each protein 
from its cluster centroid. While this summed distance necessarily became smaller as more clusters 
were added, the rate of decline decreased with each added group, eventually settling at a fairly 
constant rate of decline that reflected over-fitting; clusters added prior to this point reflected 
underlying structure in the protein data, while clusters subsequently added through over-fitting 
were not informative. The point of inflexion fell at or after nine classes, indicating that there were 
at least nine classes of proteins displaying different expression profiles across the protein samples. 
The panels on the right show examples of proteins belonging to classes 1, 4, 5 and 9, which contain 
the 7 proteins degraded early and late during infection (Figure 2C). A full list of proteins in each 



































Figure S2. (A) Immunofluorescence demonstrated diffuse cytoplasmic colocalisation between 
MLKL-HA and pUL36-V5 in stably co-transduced HFFF-TERTs. (B) Immunoblot showing that 
pUL36 is sufficient to downregulate MLKL. Expression of 17/21 V5-tagged viral proteins was 
confirmed by anti-V5 immunoblot. Expression of pUL135, pUL146 and pUL147 was confirmed 
by mass spectrometry (9). pUL136 was not detected by either method; further confirmation that 
pUL136 does not affect MLKL levels is required, although this protein was not detected in the 
SILAC IP of MLKL-HA in HCMV-infected cells (Figure 3C). A faint band corresponding to 
pUL148C could be detected upon over-exposure of the blot (bottom right panel). (C) 
Densitometry analysis of MLKL expression normalised by GAPDH expression in each cell line. 
Expression of UL36 was sufficient to reduce the level of MLKL by 3.7-fold. MLKL expression 
was not modulated more than 2-fold by other proteins in the UL/b’ region.  (D) Despite 
substantial variation in the level of expression of some of the viral proteins, this did not correlate 
with relative MLKL abundance. For every cell line in which V5 was detectable by 
immunoblotting, the relative abundances of MLKL (adjusted to GAPDH) and the V5-tagged viral 
protein (adjusted to GAPDH) were calculated. To prevent confounding effects from systematic 
expression level differences between each of the three blots, values derived from each blot were 
normalised to the maximum level of MLKL and V5 expression prior to comparison. No 
correlation between MLKL and V5 expression was observed. (E) Immunoblot confirming that 
MLKL is degraded by HCMV strain Merlin in cells solubilised in 2% SDS as well as in cells 
lysed in RIPA buffer (Figure 3B). The level of MLKL was partially recovered by addition of 
MG132, indicating active degradation (MOI = 5, 48 h infection). MG132 at a final concentration 
of 10 µM or an equivalent volume of DMSO was added to media for the last 12 h of infection. 
(F) Immunoblot confirming that MLKL is downregulated by pUL36 in cells solubilised in 2% 















Figure S3. pUL36 interacts with unphosphorylated MLKL. Amino acid sequence of MLKL, with 
the peptides identified in the pUL36-V5 IP (Figure 3D) highlighted in different colours according 
to the frequency of identification. Thr357 and Ser358 are phosphorylated by RIP3 during TNFα-
stimulated necroptosis (19). Ser125 is phosphorylated in a cell-cycle dependent manner but its 
















Figure S4. (A) Expression of RIP1 and RIP3 in HFFF-TERTs quantified by proteomics (the 
experimental setup is described in Figure 2). RIP3 was only detected in the first of two biological 
replicates. *p<0.05. (B) Cell death in HFFF-TERTs is stimulated by BV6 (B) alone, TNFα + BV6 
(TB), and TNFα + BV6 + Z-VAD-fmk (TBZ). In addition to apoptosis stimulated by TB and 
necroptosis stimulated by TBZ, HFFFs also underwent cell death in response to B alone, which has 
been described in other cell types (22). Cell death in MEFs was additionally stimulated by TZ, 
which has been observed in other mouse fibroblast cell lines (23). Each treatment was applied for 
18 h. Error bars show standard error of the mean (SEM). Data are representative of three 
independent experiments. (C) Cell death in HFFF-TERTs stimulated by TBZ is RIP3- and MLKL-
dependent, whereas B or TB stimulate pathways independent of RIP3 and MLKL. Cells were 
treated for 18 h in the presence or absence of necrosulfonamide (NSA) or GSK’872. Application 

























Figure S5. Amino acid sequence alignment of pUL36 from HCMV strains Merlin and AD169 
using Clustal Omega by EMBL-EBI (15). The five amino acid sequence differences are 
highlighted. ‘*’ indicates positions which have an identical, fully conserved residue. ‘:’ indicates a 
substitution with a residue with strongly similar properties. ‘.’ indicates a substitution with a residue 







Supplementary Information Legends for Datasets 
 
Dataset S1 (separate .xls file). Interactive spreadsheet of all TMT-based proteomic data in this 
paper. The ‘Plotter’ worksheet generates graphs of protein abundance for any human or viral 
protein quantified across each experiment. The ‘Data’ worksheet shows minimally annotated 
protein data, for which the only modifications are formatting, deletion of contaminants, 
normalisation and reassignment of non-canonical HCMV ORFs. The ‘K-means clusters’ worksheet 
shows the human proteins belonging to each cluster from Figure S1B. 
Dataset S2 (separate .xls file). Data from the MLKL-HA (denoted ‘HA’) and pUL36-V5 (denoted 
‘V5’) SILAC immunoprecipitations. 
Dataset S3 (separate .xls file). (A) Oligonucleotides employed in PCR amplification of MLKL-
HA and the V5-tagged viral genes used in the study. (B) Confirmed sequences of MLKL-HA and 
the viral genes UL36 and UL133-150A. (C) Oligonucleotides employed for site-directed 
mutagenesis of UL36. (D) Method of cloning and verification of expression of each of the viral 
genes UL36 and UL133-150A. 
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